A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...

A bipartisan group of senators are filing a bill that would force health insurers or PBMs to divest their pharmacy businesses ...

David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...

Prescriptions for weight-loss drugs surged in 2024 and were much more popular in some states, particularly those in the South ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...

Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.

According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Novo Nordisk is a bargain stock with tremendous growth potential. Vertex Pharmaceuticals has seven clear paths to growth ...

People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...